Capital World Investors Lowers Stock Position in IQVIA Holdings Inc. (NYSE:IQV)

Capital World Investors lessened its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 11.8% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 587,870 shares of the medical research company's stock after selling 78,824 shares during the quarter. Capital World Investors owned 0.32% of IQVIA worth $115,522,000 as of its most recent SEC filing.

Several other institutional investors have also recently bought and sold shares of the business. Synergy Asset Management LLC acquired a new stake in shares of IQVIA in the 4th quarter worth about $33,000. GKV Capital Management Co. Inc. purchased a new stake in shares of IQVIA in the fourth quarter worth approximately $39,000. Lee Danner & Bass Inc. purchased a new position in shares of IQVIA during the fourth quarter valued at approximately $44,000. Zions Bancorporation N.A. grew its holdings in IQVIA by 55.2% during the fourth quarter. Zions Bancorporation N.A. now owns 239 shares of the medical research company's stock worth $47,000 after buying an additional 85 shares in the last quarter. Finally, Versant Capital Management Inc raised its position in IQVIA by 46.0% in the 4th quarter. Versant Capital Management Inc now owns 295 shares of the medical research company's stock valued at $58,000 after buying an additional 93 shares during the last quarter. Institutional investors and hedge funds own 89.62% of the company's stock.

IQVIA Price Performance

Shares of IQV traded down $0.30 during midday trading on Friday, hitting $150.38. 1,333,062 shares of the company traded hands, compared to its average volume of 1,420,530. IQVIA Holdings Inc. has a one year low of $135.97 and a one year high of $252.88. The firm has a market cap of $26.51 billion, a P/E ratio of 20.05, a PEG ratio of 1.99 and a beta of 1.46. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.84 and a quick ratio of 0.84. The stock has a 50-day moving average of $171.60 and a 200-day moving average of $194.05.

IQVIA (NYSE:IQV - Get Free Report) last posted its earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. As a group, sell-side analysts predict that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on the stock. Royal Bank of Canada reiterated an "outperform" rating and issued a $270.00 target price on shares of IQVIA in a research note on Monday, February 10th. UBS Group decreased their price objective on shares of IQVIA from $260.00 to $255.00 and set a "buy" rating for the company in a research note on Friday, February 7th. HSBC downgraded IQVIA from a "buy" rating to a "hold" rating and cut their target price for the stock from $260.00 to $160.00 in a research note on Friday. Hsbc Global Res downgraded IQVIA from a "strong-buy" rating to a "hold" rating in a research report on Friday. Finally, Mizuho reduced their price objective on IQVIA from $242.00 to $210.00 and set an "outperform" rating for the company in a research note on Wednesday, April 9th. Eight research analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $237.62.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.